Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adhera Therapeutics (ATRX)
OTHER OTC:ATRX
Holding ATRX?
Track your performance easily
ATRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $0.04
Previous Close$0.01
Volume1.30K
Average Volume (3M)N/A
Market Cap
$1.44K
Enterprise Value$10.80M
Total Cash (Recent Filing)$32.39K
Total Debt (Recent Filing)$10.83M
Price to Earnings (P/E)―
Beta-4.37
Next Earnings
May 18, 2018EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding7,220,900
10 Day Avg. Volume138
30 Day Avg. VolumeN/A
Standard Deviation1.56
R-Squared0.01
Alpha0.18
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRX FAQ
What was Adhera Therapeutics’s price range in the past 12 months?
Adhera Therapeutics lowest stock price was <$0.01 and its highest was $0.04 in the past 12 months.
What is Adhera Therapeutics’s market cap?
Currently, no data Available
When is Adhera Therapeutics’s upcoming earnings report date?
Adhera Therapeutics’s upcoming earnings report date is May 18, 2018 which is 2411 days ago.
How were Adhera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Adhera Therapeutics overvalued?
According to Wall Street analysts Adhera Therapeutics’s price is currently Overvalued.
Does Adhera Therapeutics pay dividends?
Adhera Therapeutics does not currently pay dividends.
What is Adhera Therapeutics’s EPS estimate?
Adhera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adhera Therapeutics have?
Adhera Therapeutics has 7,220,900 shares outstanding.
What happened to Adhera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adhera Therapeutics?
Currently, no hedge funds are holding shares in ATRX
---
Company Description
Adhera Therapeutics
Adhera Therapeutics, Inc. engages in the discovery, development, and commercialization of drug therapeutics for hypertension. It offers Perstalia, which contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension. The company was founded on September 23, 1983 and is headquartered in Durham, NC.
---
Anixa Biosciences
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Cyclacel Pharmaceuticals
―
---